Bionano Symposium 2026 continues with Day 2: New Frontiers in Oncology and Bioprocessing Applications on February 24, 2026, from 7:00-10:00 AM PT. Attendees may also explore scientific posters ...
Financial Conflicts of Interest: Payment at the Expense of Patients? In the article that accompanies this editorial, Weisse et al 11 present new findings about residential hospice care for patients ...
Hematological malignancies encompass a diverse range of diseases, such as leukemia, lymphoma, and multiple myeloma, among others. Within the multidisciplinary treatment approach, radiation therapy ...
Table 1. Common causes and pathogenic mechanisms of acute and chronic renal impairment in patients with hematological malignancies. Category Causes and pathogenetic mechanisms Ref. Disease related ...
Lactic acidosis represents a challenging metabolic complication in patients with haematological malignancies. Notably, type B lactic acidosis occurs in the absence of hypoxia and is associated with ...
Early in 2024, we reported on the FDA's call for new boxed warnings on the labeling of all approved chimeric antigen receptor (CAR) T-cell therapies for the potential risk for secondary T-cell ...
The CAR T-cell therapy market is ripe for growth with over 250 companies and 500 drugs in development globally. Key opportunities lie in targeting hematologic malignancies and overcoming challenges in ...
Olalekan O. Oluwole discusses how CAR T-cell therapy is used to treat high-risk hematologic malignancies like lymphoma and leukemia. CAR T-cell therapy is a unique way of treating hematologic ...
Fewer than 1% of all causes of ascites are attributed to conditions other than liver cirrhosis, cardiac disease or malignancy. In this case, the patient presented with massive splenomegaly and later ...
The FDA recommends health care providers consider alternative therapies given the risks associated with Skysona. The Food and Drug Administration (FDA) is investigating additional reports of ...
Hematologic malignancy patients face high COVID-19 risk, with 23.5% experiencing severe illness despite vaccination. Mortality rate was 22.4%, influenced by age, active disease, and ICU admission.
Skysona will now only be indicated for patients without an available HLA-matched allogeneic hematopoietic stem cell donor. The Food and Drug Administration (FDA) has approved new safety labeling ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results